3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Withdrawn
1
Unknown
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
COVID-19
2
Skin Neoplasms
1
Respiratory Sounds
1
Neoplasms
1
Lymphoma, Follicular
1
Hematologic Neoplasms
1
Crohn Disease
1
Asthma
1
Interventions
Surveys and Questionnaires
6
Standard of Care
6
Blood Specimen Collection
6
BNT162 Vaccine
5
Hydroxychloroquine
4
Surgical Procedures, Operative
3
Specimen Handling
3
Practice Guidelines as Topic
3
COVID-19 Vaccines
3
2019-nCoV Vaccine mRNA-1273
3
tocilizumab
2
sotrovimab
2
Pandemic Preparedness
2
CVnCoV COVID-19 vaccine
2
Azithromycin
2
sinovac COVID-19 vaccine
1
selinexor
1
remdesivir
1
ogalvibart
1
monalizumab
1
lenzilumab
1
heterologous prime boost COVID-19 vaccination
1
crexavibart
1
cilgavimab and tixagevimab drug combination
1
ciclesonide
1
avdoralimab
1
XAV-19
1
Therapeutics
1
Telemedicine
1
Sperm Count
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
COVID-19
×
Azithromycin
×
Clear all
NCT04392128
2020-09-04
HYACINTHE
Institut de cancérologie Strasbourg Europe
Phase 2
Withdrawn
NCT04341207
2020-04-10
ONCOVID
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Unknown
1,000 enrolled